Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

NCT03447132 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

354

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm Female

Interventions

DRUG: Fulvestrant 500mg
DRUG: Palbociclib 125mg
DRUG: Goserelin 3.6 MG
DRUG: Placebos

Sponsor

International Cancer Research Group, United Arab Emirates

Collaborators

[object Object]
[object Object]
[object Object]